LLY vs PFE
LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | LLY | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-09 close | $1,179.27 | $28.28 | |
| Market cap | $1.11T | $161.2B | |
| P/E as of 2026-10-09 | 39.58 | 37.44 | PFE lower |
| PEG as of 2026-10-09, 3-year EPS CAGR to FY2025 | 0.80 | n/a | |
| Net margin FY2025, SEC XBRL | +31.7% | +12.4% | LLY higher |
| ROE FY2025, SEC XBRL | +77.8% | +9.0% | LLY higher |
| ROA FY2025, SEC XBRL | +18.4% | +3.7% | LLY higher |
| Debt / equity as of 2026-09-03 | 1.62 | 0.74 | PFE lower |
| Revenue growth (YoY) as of 2026-09-03 | +49.6% | -0.2% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | -14.8% | LLY higher |
| Dividend yield as of 2026-09-03 | +0.6% | +6.2% | PFE higher |
| Dividend streak (yrs) SEC XBRL | 10 | 11 | PFE higher |
| Beta as of 2026-09-03 | 0.55 | 0.39 | |
| 1-year return as of 2026-10-09 close | +37.9% | +12.0% | LLY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.